Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial Open Access

Author(s): Simon, Florian1; Ligtvoet, Rudy1; Bohn, Jan-Paul2; Nösslinger, Thomas3; von Tresckow, Julia4; Liersch, Rüdiger5; Gaska, Tobias6; Jentsch-Ullrich, Kathleen7; Gärtner, Michael8; Wolff, Thomas9; Schwaner, Ingo10; Wolf, Dominik2; Schneider, Christof11; Vehling-Kaiser, Ursula12; Ritgen, Matthias13; Spoer, Christian14; Eckart, Michael15; Decker, Thomas16; Chakupurakal, Geothy17; Schöttker, Björn18; Kisro, Jens19; Kreuzer, Karl-Anton1; Tausch, Eugen11; Stilgenbauer, Stephan11; Robrecht, Sandra1; Stumpf, Janina1; Fink, Anna-Maria1; Fürstenau, Moritz1; Fischer, Kirsten1; Goede, Valentin20; Hallek, Michael1; Eichhorst, Barbara1;
Source: Blood (2025) 146 (26): 3153–3162.
Original Article
Professional photo of Maem Hussein, MD

Dr. Maen Hussein's Thoughts

Acalabrutinib in patients aged ≥80 years demonstrated 12-month progression-free (PFS) and overall survival (OS) rates of 93.3% and 95.7%, respectively, after a median follow-up of 19 months. Adverse events were severe but rarely included major bleeding or atrial fibrillation. Patient-reported quality of life improved, including amerlioration of frailty.

ABSTRACT

Because frail patients and patients aged ≥80 years with chronic lymphocytic leukemia (CLL) are still underrepresented in clinical trials, the CLL-Frail trial aimed to evaluate the efficacy and safety of acalabrutinib in these patients. The primary end point was the overall response rate (ORR) after 6 cycles of treatment to test the null hypothesis of ORR ≤65%. Fifty-three patients were included in the trial, and 34 patients are still on therapy. Adverse events (AEs) were the most frequent reason for early discontinuation (10 patients), whereas 5 patients stopped treatment because of death. Median age was 81 years, and 47.2% of patients were frail. The ORR for the 46 patients receiving ≥3 cycles of treatment was 93.5% (95% confidence interval, 82.1-98.6) meeting the primary end point of this trial (P < .001). The estimated 12-month progression-free and overall survival rates were 93.3% and 95.7%, respectively, after a median follow-up of 19 months. 53.5% of patients reported an improvement in their self-perceived frailty. Although all patients experienced AEs, and severe (Common Terminology Criteria of ≥3) events were reported in 63.5% of patients, there were no events of severe bleeding and atrial fibrillation was rare (2 cases of Common Terminology Criteria Grades 2 and 3). Five patients died, of which 4 deaths happened during or <28 days after treatment. Infections/COVID-19 were the cause of death in 3 cases. To our knowledge, this is the first prospective trial in older and/or frail patients with CLL demonstrating a high efficacy and safe treatment with acalabrutinib monotherapy. This trial was registered at www.ClinicalTrials.gov as #NCT04883749.

Author Affiliations

1Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne, Germany; 2Department of Internal Medicine V–Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria; 3Third Medical Department for Hematology and Oncology, Hanusch Krankenhaus Wien, Vienna, Austria; 4Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 5Gemeinschaftspraxis für Hämatologie und Onkologie, Clemenshospital Münster, Münster, Germany; 6Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie und Onkologie, Paderborn, Germany; 7Gemeinschaftspraxis für Hämatologie und Onkologie, Magdeburg, Germany; 8Onkologisches Ambulanzzentrum Hannover, Hannover, Germany; 9OncoResearch Lerchenfeld, Hamburg, Germany; 10Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany; 11Department of Internal Medicine III, Sektion CLL, Ulm University, Ulm, Germany; 12Outpatient Clinic, Landshut, Germany; 13Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany; 14MVZ Klinikum Deggendorf, Deggendorf, Germany; 15Practice for Oncology and Hematology, Erlangen, Germany; 16Oncological Practice, Ravensburg, Germany; 17Praxis für Hämatologie und Onkologie, Koblenz, Germany; 18Practice for Oncology and Hematology, Würzburg, Germany; 19Lübecker Onkologische Schwerpunktpraxis, Lübeck, Germany; 20Department of Oncogeriatrics, St Marien Hospital, Cologne, Germany

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial Open Access

This is an impressive advance in allo transplant, Orca-T cutting moderate–severe cGVHD dramatically (≈13% vs 44%) and nearly doubling cGVHD-free survival at 1 year (78% vs 38%) while also lowering NRM and serious infections is hard to ignore. Overall survival (OS) isn’t statistically different yet, but the combination of better disease control, less toxicity, and preserved immune reconstitution makes this feel like a meaningful step toward safer, more “engineered” transplants rather than just better immunosuppression.

Read More »

Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial Open Access

This is starting to look like a real frontline disruptor in chronic myeloid leukemia (CML), asciminib showing a pretty striking ~22% absolute improvement in MMR at 96 weeks vs investigator-selected TKIs (and nearly 30% over imatinib) with a cleaner tolerability profile makes a strong case for moving beyond ATP-competitive tyrosine kinase inhibitors (TKIs) upfront. The efficacy signal is consistent across depths of response and durability looks excellent, with fewer discontinuations, overall survival (OS) will take time, but this feels very competitive as a new standard option.

Read More »

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

CLL17 shows that fixed‑duration venetoclax–obinutuzumab or venetoclax–ibrutinib is noninferior to continuous ibrutinib upfront, with 3‑year PFS ≈80% across all arms. The big difference is depth of response, undetectable MRD was 73% with venetoclax–obinutuzumab, 47% with venetoclax–ibrutinib, and 0% with ibrutinib. Toxicities tracked with mechanism (more cytopenias/infusion reactions with ven‑obinutuzumab, more cardiac events with ibrutinib). Overall, this strongly supports time‑limited therapy as a frontline standard for many chronic lymphocytic leukemia (CLL) patients.

Read More »

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????

Read More »

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML

Ziftomenib 600 mg daily achieved a CR/CRh rate of 22% (61% MRD-negative among responders) and an overall response rate (ORR) of 33% in heavily pretreated R/R NPM1-mutated AML, with a median duration of response (DOR) of 4.6 months and median overall survival (OS) of 6.6 months (18.4 months in responders). Efficacy was consistent across subgroups, including prior venetoclax and FLT3/IDH co-mutations, and safety was manageable with on-target differentiation syndrome in 25% (15% grade 3; no grade 4–5), low myelosuppression, rare QTc prolongation (3%), and only 3% discontinuations for drug-related AEs. This non-cytotoxic, oral menin inhibitor offers meaningful activity in a high-risk population and is a practical option while we await combination data.

Read More »
Load More